Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23887607 | 0.86 | SYK (0.42) | KMT2AMEN1PIM1NPC1RAB9A | |
| SCHEMBL1950236 | 0.80 | KMT2A (0.64) | KMT2AMEN1MAPK10GFERPIM1 | |
| SCHEMBL4897079 | 0.80 | KMT2A (0.64) | KMT2AMEN1MAPK10GFERPIM1 | |
| SCHEMBL221242 | 0.79 | KMT2A (0.76) | KMT2AMEN1MAPK10GFERNPC1 | |
| SCHEMBL29391624 | 0.79 | KMT2A (0.76) | KMT2AMEN1MAPK10GFERNPC1 | |
| SCHEMBL3988183 | 0.79 | AURKA (0.65) | KMT2AMEN1PIM1NPC1RAB9A | |
| SCHEMBL4595845 | 0.79 | KMT2A (0.48) | KMT2AMEN1MAPK10GFERPIM1 | |
| SCHEMBL28965358 | 0.79 | ASIC3 (0.50) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24304970 | 0.79 | SCN9A (0.48) | PIM1NPC1RAB9AALDH1A1SYK | |
| SCHEMBL20325387 | 0.78 | NPC1 (0.55) | KMT2AMEN1MAPK10GFERPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518078-B | Aminopyridine-containing pyrimidine compound and application thereof | 南方医科大学 | 2021-02-26 | — | — | CN | claimed |
| CN-111518078-A | Aminopyridine-containing pyrimidine compound and application thereof | 南方医科大学 | 2020-08-11 | — | — | CN | claimed |
| EP-1742634-B1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-7560464-B2 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1742634-A1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAgen, Incorporated (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005099711-A1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | KCNJ2, KCNJ1, KCNJ11 | KMT2A 908/4885MEN1 3752/4885MAPK10 1898/4885 |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | KMT2A 2974/4885MEN1 1164/4885MAPK10 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.